Literature DB >> 10584665

Excessive daytime sleepiness and sleep benefit in Parkinson's disease: a community-based study.

E Tandberg1, J P Larsen, K Karlsen.   

Abstract

The objective of this study was to investigate the frequency of excessive daytime sleepiness (EDS) and the beneficial effect of sleep on motor performance in an unselected community-based sample of patients with Parkinson's disease (PD). Furthermore, we wanted to identify possible risk factors to these phenomena. Detailed information on somnolence and sleep during daytime, as well as sleep benefit (SB) on awakening, was collected through a questionnaire among 245 patients with PD. Daytime somnolence was graded in groups of no somnolence, mild daytime sleepiness, and EDS. In addition, the occurrence of somnolence in the patients with PD was compared with the occurrence among control groups of patients with diabetes mellitus and of healthy elderly subjects. The correlations between EDS and SB and various motor- and non-motor symptoms of PD were evaluated. Among the patients with PD, 15.5% experienced EDS, significantly more than in the patients with diabetes mellitus (4%) and the healthy control subjects (1%). The frequency of mild daytime sleepiness was similar (10%) in patients with PD and control subjects. The patients with EDS had significantly higher staging of PD, were more disabled, and showed a higher frequency of cognitive decline compared with the patients without somnolence. They also had been using levodopa for a longer time and had more hallucinations. The occurrence of nocturnal sleeping problems and the use of sleeping pills was similar in the two groups, as was the mean age at examination, duration of PD, and presence of fluctuations and dyskinesias. SB was found in 42.2% of the patients with PD. These patients had been using levodopa for significantly longer and had significantly more fluctuations and dyskinesias compared with the patients without SB. Our results suggest that mild daytime sleepiness may be a result of normal aging, whereas more severe EDS can be explained by the neuropathologic changes of PD. The data from this community-based study confirms the previously reported high frequencies of SB.

Entities:  

Mesh:

Year:  1999        PMID: 10584665     DOI: 10.1002/1531-8257(199911)14:6<922::aid-mds1003>3.0.co;2-7

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  60 in total

1.  The Parkinson's disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson's disease.

Authors:  K R Chaudhuri; S Pal; A DiMarco; C Whately-Smith; K Bridgman; R Mathew; F R Pezzela; A Forbes; B Högl; C Trenkwalder
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-12       Impact factor: 10.154

2.  Clinical correlates of periodic limb movements in sleep in Parkinson's disease.

Authors:  Naima Covassin; Ariel B Neikrug; Lianqi Liu; Jody Corey-Bloom; Jose S Loredo; Barton W Palmer; Jeanne Maglione; Sonia Ancoli-Israel
Journal:  J Neurol Sci       Date:  2012-01-25       Impact factor: 3.181

3.  Parkinsonism with excessive daytime sleepiness--a narcolepsy-like disorder?

Authors:  Christian Baumann; Luigi Ferini-Strambi; Daniel Waldvogel; Esther Werth; Claudio Lino Bassetti
Journal:  J Neurol       Date:  2005-02       Impact factor: 4.849

Review 4.  Neurologic conditions: assessing medical fitness to drive.

Authors:  Steven H Yale; Phiroze Hansotia; Dawn Knapp; John Ehrfurth
Journal:  Clin Med Res       Date:  2003-07

5.  Quantitative Motor Performance and Sleep Benefit in Parkinson Disease.

Authors:  Merel M van Gilst; Petra van Mierlo; Bastiaan R Bloem; Sebastiaan Overeem
Journal:  Sleep       Date:  2015-10-01       Impact factor: 5.849

6.  Cross-cultural adaptation and psychometric properties of the SCOPA-Sleep-German version.

Authors:  Simone Goebel; Elisabeth Steinmann; Bernd Leplow; H Maximilian Mehdorn
Journal:  Neurol Sci       Date:  2018-04-14       Impact factor: 3.307

7.  Therapeutic potential of melatonin and its analogs in Parkinson's disease: focus on sleep and neuroprotection.

Authors:  Venkatramanujam Srinivasan; Daniel P Cardinali; Uddanapalli S Srinivasan; Charanjit Kaur; Gregory M Brown; D Warren Spence; Rüdiger Hardeland; Seithikurippu R Pandi-Perumal
Journal:  Ther Adv Neurol Disord       Date:  2011-09       Impact factor: 6.570

8.  Hallucinations, dreaming, and frequent dozing in Parkinson disease: impact of right-hemisphere neural networks.

Authors:  Karina Stavitsky; Patrick McNamara; Raymon Durso; Erica Harris; Sanford Auerbach; Alice Cronin-Golomb
Journal:  Cogn Behav Neurol       Date:  2008-09       Impact factor: 1.600

Review 9.  Parkinson's disease: the quintessential neuropsychiatric disorder.

Authors:  Daniel Weintraub; David J Burn
Journal:  Mov Disord       Date:  2011-05       Impact factor: 10.338

Review 10.  Excessive daytime sleepiness and sleep disturbances in patients with neurological diseases: epidemiology and management.

Authors:  Svenja Happe
Journal:  Drugs       Date:  2003       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.